Healthcare Author: Mengyao Zhang Jul 13, 2020 06:48 PM (GMT+8)

CSPC Pharmaceutical has seized the chance of entry into the third national centralized procurement and expects stable sales for the generic drug Celecoxib.

Image credit: EqualOcean

CSPC Pharma’s Celecoxib is the generic COX-2 form of Celebrex, used to treat  pain and inflammation in osteoarthritis, acute pain in rheumatoid arthritis, ankylosing spondylitis, painful menstruation and other related syndromes.

As released officially today, CSPC’s Celecoxib was approved by the National Medical Products Administration, which is seen as an approval of the consistency evaluation for generic drugs. The medicine has been listed in the third national centralized procurement and selected for the third national centralized procurement.

CSPC Pharmaceutical, together with two brands (Hengrui Medicine and Zhengda Qingjiang Pharmacy) of the generic drugs of Celecoxib, will compete against the original developer Pfizer in procurement supplies.